Frost & Sullivan insights
Different from the in-depth development of large language modelsOpenAI, GoogleDeepMindIn the field of structural biology, as we delve deeper, starting from attempting to predict the three-dimensional structure of proteins, we have now achieved predictions for most life molecules. This year5monthDeepMindlaunchAlphaFold 3, go straight for itnatureHeadlines, attracting widespread attention within the industry.Alphafold 3representative of the same kindAIWhat impacts has the tool had on the development of the medical industry? What is the prospect for technology applications?AIIn structural biology, as well as across the entire healthcare sector, how can large-scale commercialization be achieved? What other barriers need to be broken down?Alphafold 3Under the impact, our countryAIHow should enterprises and related pharmaceutical companies deploy their strategies?
Frost & SullivanFrost & Sullivan,Zhou Mingzi, Executive Director of Greater China at 'Frost & Sullivan' (hereinafter referred to as 'Frost & Sullivan'), answered21Financial interviews, discussing togetherAIImpact on the healthcare industry.
21Finance and Economics
*Click at the end of the article Read the original text View the full report
Q: withAlphafold 3representative of the same kindAIWhat impacts has the tool had on the development of the medical industry? What are the prospects for technology applications?
withAlphaFold 3representative of the same kindAITools have had a profound impact on the development of the medical industry. By accurately predicting biomolecular structures, they have accelerated the drug research and development process, promoted the development of precision medicine, and facilitated scientific research cooperation and exchange. These technical tools not only improve the efficiency and success rate of drug research and development but also provide new perspectives for a deeper understanding of disease mechanisms. In the future, with continuous technological maturity and expansion of application fields,AIThe application prospects of tools in the medical field are expected to be even broader, promising more innovation and transformation for the healthcare industry. However, challenges such as technical maturity, data security and privacy protection, as well as regulatory policies, also need to be addressed.
Q: AIIn structural biology, as well as across the entire healthcare sector, how can large-scale commercialization be achieved? What other barriers need to be broken down?
AITo achieve large-scale commercialization and implementation in structural biology and the entire healthcare field, continuous technological maturation and application expansion are necessary, such asAlphaFold 3The successful application in protein structure prediction has advanced the process of drug research and development and disease mechanism studies. However, to achieve this goal, multiple barriers need to be overcome, including further improvement in technical maturity and reliability, accumulation and integration of high-quality medical data, refinement of data privacy and security protection mechanisms, as well as the formulation of regulatory policies and standards that adapt to industry characteristics. In addition, cross-border cooperation and industrial integration are also drivingAIAn important path for commercial implementation in the medical field.
Q: atAlphafold3Under the impact, our countryAIHow should enterprises and related pharmaceutical companies deploy their strategies?
atAlphafold 3Under the impact, our countryAIEnterprises and related pharmaceutical companies should actively deploy strategies to address challenges and seize opportunities. Specifically,AIEnterprises can increase investment in deep learning,TransformeranddiffusionInvest in cutting-edge technologies such as models to improve model prediction accuracy and generalization ability. At the same time, explore in-depth integration with the biomedical field, and develop more models with practical application value.AItools. In terms of pharmaceutical companies, they should strengthenAIEnterprise cooperation, utilizationAIAccelerates the new drug R&D process with technology, improves R&D efficiency and success rate, while paying attention toAIIn the application of drug optimization and disease diagnosis, technological innovation is used to drive industrial upgrading. In addition, both parties should also pay joint attention to data security and privacy protection, ensuring that while promoting technological progress, it complies with laws, regulations, and ethical requirements.
*This interview has been published in 21Finance and Economics Reporter: Yan Shuo, original title: 'From Prediction to Reality,AlphaFold 3How to Empower the Life and Health Sector?
